Stoudemire A, Knos G, Gladson M, Markwalter H, Sung Y F, Morris R, Cooper R
Department of Psychiatry, Emory University School of Medicine, Atlanta, Ga.
J Clin Psychiatry. 1990 Dec;51(12):508-12.
Labetalol, a drug with alpha- and beta-adrenergic receptor blocking effects, was used to attenuate hypertension and tachycardia associated with electroconvulsive therapy (ECT) in a series of 11 elderly patients with refractory depression and cardiovascular disease in a placebo-controlled, double-blind crossover study design. As compared with placebo, labetalol was found to blunt mean arterial pressure (MAP) increase by up to 8.26% (p less than .001), heart rate increased by up to 26.07% (p less than .001), frequency of atrial arrhythmias by up to 100% (p less than .01), and premature ventricular contractions by 41.97%. No untoward side effects were observed, and no effect on treatment outcome was noted. Labetalol appears to be an effective and safe agent to use in decreasing hypertension, tachycardia, and possibly arrhythmias in high-risk medical patients with cardiovascular disease undergoing ECT.
拉贝洛尔是一种具有α和β肾上腺素能受体阻滞作用的药物，在一项安慰剂对照、双盲交叉研究设计中，对11例患有难治性抑郁症和心血管疾病的老年患者使用该药，以减轻与电休克治疗（ECT）相关的高血压和心动过速。与安慰剂相比，发现拉贝洛尔可使平均动脉压（MAP）升高幅度降低多达8.26%（p<0.001），心率升高幅度降低多达26.07%（p<0.001），房性心律失常频率降低多达100%（p<0.01），室性早搏降低41.97%。未观察到不良副作用，也未发现对治疗结果有影响。拉贝洛尔似乎是一种有效且安全的药物，可用于降低接受ECT的患有心血管疾病的高危内科患者的高血压、心动过速，并可能减少心律失常。
